share_log

Juva Life Reports Strong Growth in Q3 2023 Financial Results

Juva Life Reports Strong Growth in Q3 2023 Financial Results

Juva Life公布2023年第三季度财务业绩强劲增长
Accesswire ·  2023/12/13 03:00

REDWOOD CITY, CA / ACCESSWIRE / December 13, 2023 / Juva Life Inc. (CSE:JUVA)(OTCQB:JUVAF)(FRANKFURT:4VV) ("Juva Life" or the "Company"), Juva Life, Inc, a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, is delighted to announce its financial results for the third quarter ending September 30, 2023.

加利福尼亚州雷德伍德城/ACCESSWIRE/2023年12月13日/Juva Life Inc.(CSE: JUVA)(OTCQB: JUVAF)(法兰克福:4VV)(“Juva Life” 或 “公司”),Juva Life, Inc.是一家在大麻生产和分销方面兼具药物研发和面向消费者的业务的生命科学公司,很高兴地宣布其第三季度的财务业绩将于 2023 年 9 月 30 日结束。

Key Highlights:

主要亮点:

  • Revenue Growth: Juva Life reported a substantial increase in sales, with Q3 2023 sales reaching $3.17 million, compared to $1.25 million for the same period in 2022.
  • Cost Reduction: The company successfully reduced its net loss for Q3 2023 to $782K, a significant improvement compared to a net loss of $2.9 million in Q3 2022.
  • Operational Expansion: The completion of construction and full operational capability at the San Juan Facility in Stockton, California, has contributed to increased cultivation, manufacturing, distribution capacity, and a related increase in revenue.
  • Retail Growth: The addition of a retail store, operational as of June 2023, at the intersection of Broadway and Hamilton streets in Redwood City, CA, has further expanded Juva's presence, complementing its delivery services throughout the Bay Area Peninsula.
  • 收入增长:Juva Life报告销售额大幅增长,2023年第三季度的销售额达到317万美元,而2022年同期为125万美元。
  • 降低成本:该公司成功将其2023年第三季度的净亏损减少至78.2万美元,与2022年第三季度的净亏损290万美元相比,有了显著改善。
  • 业务扩张:位于加利福尼亚州斯托克顿的圣胡安工厂竣工并具备全面运营能力,促进了种植、制造、分销能力的提高以及相关的收入增长。
  • 零售增长:在加利福尼亚州雷德伍德城的百老汇街和汉密尔顿街交汇处增加了一家零售店,该商店将于2023年6月开始运营,这进一步扩大了Juva的影响力,补充了其在整个湾区半岛的送货服务。

Financial Overview:

财务概述:

  • Sales: Sales for the nine months ended September 30, 2023 reached $6.4 million, a 52.3% increase over the $4.2 million in revenue for the same period in 2022.
  • Net Loss: The net loss for the nine months ended September 30, 2023, was $4.2 million, a substantial improvement from the $7.9 million loss in the corresponding period in 2022.
  • 销售额:截至2023年9月30日的九个月中,销售额达到640万美元,比2022年同期的420万美元收入增长了52.3%。
  • 净亏损:截至2023年9月30日的九个月中,净亏损为420万美元,较2022年同期的790万美元亏损大幅增加。

Operational Efficiencies:

运营效率:

  • EBITDA Improvement: Despite the challenges in the industry, Juva Life achieved positive strides in operational efficiencies, with EBITDA improving from a negative $4.97 million in Q3 2022 to negative $141K in Q3 2023.
  • Adjusted Gross Margin: The adjusted gross margin for Q3 2023 reached $1.4 million compared to $377K in the same quarter of the previous year.
  • 息税折旧摊销前利润改善:尽管行业面临挑战,但Juva Life在运营效率方面取得了积极进展,息税折旧摊销前利润从2022年第三季度的负497万美元提高到2023年第三季度的负14.1万美元。
  • 调整后毛利率:2023年第三季度调整后的毛利率达到140万美元,而去年同期为37.7万美元。

Doug Chloupek, CEO and Founder of Juva Life, stated, "We are thrilled to announce our outstanding Q3 results and the successful execution of our strategic initiatives. The robust performance of our Redwood City retail store, coupled with operational achievements in our cultivation and distribution facility, reflects our commitment to innovation and operational excellence."

Juva Life首席执行官兼创始人道格·克洛佩克表示:“我们很高兴地宣布,我们出色的第三季度业绩以及战略计划的成功执行。我们的Redwood City零售商店的强劲表现,加上我们在种植和分销设施方面的运营成就,反映了我们对创新和卓越运营的承诺。”

ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder

代表董事会,
-Doug Chloupek-
道格·克洛佩克,首席执行官兼创始人

Juva Life Inc.
inquiries@juvalife.com

Juva Life Inc.
inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

关于 Juva Life Inc.(CSE:JUVA)(OTCQB:JUVAF)(FRA:4VV)

Juva Life is employing state-of-the-art pharmaceutical research and development to discover, develop and commercialize safe and effective cannabis products. The Company will leverage revenue derived from its retail operations to advance potentially valuable non-cannabinoid bioactives for consumer and pharma product applications. Find out more at:

Juva Life正在利用最先进的药物研发来发现、开发和商业化安全有效的大麻产品。该公司将利用其零售业务获得的收入,为消费品和药品应用开发具有潜在价值的非大麻素生物活性。要了解更多信息,请访问:

For further information, please contact:

欲了解更多信息,请联系:

Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com

Juva Life 投资者关系
电话: +1 833-333-5882 (JUVA)
电子邮件:inquiries@juvalife.com

SOURCE: Juva Life Inc.

来源:Juva Life Inc.


View the original press release on accesswire.com
在 accesswire.com 上查看原始新闻稿

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发